EC
RCUS icon

EntryPoint Capital’s Arcus Biosciences RCUS Stock Holding History

EntryPoint Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$408K Buy
+13,224
New +$327K 0.1% 404
2024
Q4 		– Sell
-26,389
Closed -$403K – 923
2024
Q3 		$403K Buy
26,389
+21,385
+427% +$337K 0.23% 126
2024
Q2 		$76.2K Buy
+5,004
New +$80.8K 0.04% 931

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

EntryPoint Capital's RCUS Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 13,224 shares worth $408K. The stake represents 0.1% of the portfolio and ranks #404 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in RCUS as recently as Q3 2024.

EntryPoint Capital first reported a position in RCUS in Q2 2024 and has held it in 3 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • EntryPoint Capital held 13,224 shares of Arcus Biosciences worth $408K as of Q2 2026.
  • Arcus Biosciences was a new EntryPoint Capital position in Q2 2026.
  • Arcus Biosciences made up 0.1% of EntryPoint Capital's portfolio in Q2 2026, its #404 holding.
  • EntryPoint Capital first reported a position in Arcus Biosciences in Q2 2024 and has held it in 3 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.